Program
delgocitinib
Also written as “Delgocitinib cream”, “Delgocitinib” and “LEO 124249”.
Its studies are mostly in Eczema · Psoriasis · Dermatitis, Atopic · Alopecia Areata · Lichen Sclerosus et Atrophicus, led by LEO Pharma.
Drug pageDelgocitinib: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharma | 212 open or running | phase 3since Apr 29, 2021 | Sep 25, 2015 | Jun 4, 2027phase 2 · NCT07013201 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Sep 25, 2015 to Jan 30, 2019.
- Jun 9, 2017Named delgocitinibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LEO 124249
- May 20, 2019Phase 2 study in Lupus Erythematosus, DiscoidNCT03958955 · 27 enrolled · United States, Denmark, France and more
- Apr 22, 2020Phase 1 study in HealthyNCT04361136 · 35 enrolled · Germany
- Mar 18, 2021Phase 1 study in HealthyNCT04807751 · 60 enrolled · Germany
- Apr 29, 20212 phase 3 studies in Chronic Hand EczemaNCT04872101, NCT04871711
- Jun 29, 2021Phase 3 study in Chronic Hand EczemaNCT04949841 · 801 enrolled · Belgium, Canada, Denmark and more
- Jul 5, 2021Early phase 1 study in HealthyNCT05050279 · 40 enrolled · United Kingdom
- Feb 18, 2022Phase 3 study in Chronic Hand EczemaNCT05259722 · 513 enrolled · Austria, Canada, France and more
- Apr 11, 2022Phase 2 study in Frontal Fibrosing AlopeciaNCT05332366 · 35 enrolled · United States
- Apr 27, 2022Phase 3 study in Chronic Hand EczemaNCT05355818 · 98 enrolled · Australia, Belgium, Canada and more
- Jul 18, 2022Phase 1 study in Chronic Hand EczemaNCT05486117 · 15 enrolled · Germany
- Aug 16, 2023Phase 3 study in Skin DiseasesNCT06004050 · 362 enrolled · China
- Jun 2, 2025Phase 2 study in PsoriasisNCT07013201 · 135 planned · United States, Canada, Germany and more
- Jan 9, 2026Phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588 · 552 planned · United States, Canada, United Kingdom
- Nov 9, 2026Primary completion moved from 2026-12-14 to 2027-06-04Date moved laterphase 2 · +6 months · NCT07013201
Ahead
- Jun 4, 2027Primary completion: phase 2 study in PsoriasisNCT07013201
- Mar 10, 2028Primary completion: phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588
TargetBeta
“Janus Kinase (JAK) inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07335588Lichen Sclerosus et Atrophicus · United States, Canada, United Kingdom | 3 | Recruiting | Mar 10, 2028 | 552 |
| NCT07013201Psoriasis · United States, Canada, Germany and more | 2 | Recruiting | Jun 4, 2027 | 135 |
| NCT06004050Skin Diseases · China | 3 | Completed | Dec 16, 2024 | 362 |
| NCT05486117Chronic Hand Eczema · Germany | 1 | Completed | Nov 22, 2022 | 15 |
| NCT05355818Chronic Hand Eczema · Australia, Belgium, Canada and more | 3 | Completed | Dec 5, 2024 | 98 |
| NCT05332366Frontal Fibrosing Alopecia · United States | 2 | Completed | Feb 13, 2023 | 35 |
| NCT05259722Chronic Hand Eczema · Austria, Canada, France and more | 3 | Completed | Nov 8, 2023 | 513 |
| NCT05050279Healthy · United Kingdom | Early 1 | Completed | Jan 4, 2022 | 40 |
| NCT04949841Chronic Hand Eczema · Belgium, Canada, Denmark and more | 3 | Completed | Sep 18, 2023 | 801 |
| NCT04872101Chronic Hand Eczema · Belgium, Canada, Denmark and more | 3 | Completed | Dec 27, 2022 | 473 |
| NCT04871711Chronic Hand Eczema · Canada, France, Germany and more | 3 | Completed | Oct 31, 2022 | 487 |
| NCT04807751Healthy · Germany | 1 | Completed | Jul 30, 2021 | 60 |
| NCT04361136Healthy · Germany | 1 | Completed | May 30, 2020 | 35 |
| NCT03958955Lupus Erythematosus, Discoid · United States, Denmark, France and more | 2 | Terminated | Apr 15, 2020 | 27 |
| NCT03826901Dermatitis, Atopic · United States, Canada | 1 | Completed | Oct 29, 2021 | 46 |
| NCT03725722Dermatitis, Atopic · United States, Australia, Canada | 2 | Completed | May 19, 2020 | 251 |
| NCT03683719Chronic Hand Eczema · United States, Denmark, Germany | 2 | Completed | Mar 6, 2020 | 258 |
| NCT03325296Alopecia Areata · Denmark | 2 | Terminated | May 16, 2018 | 13 |
| NCT02695940Inverse Psoriasis · Germany | 2 | Completed | Sep 2016 | 69 |
| NCT02664805Chronic Hand Eczema · Germany | 2 | Completed | Jul 2016 | 91 |
| NCT02561585Alopecia Areata · United States | 2 | Completed | Dec 2016 | 40 |
How it is read
Names in the registry
- “Delgocitinib cream”, 9 entries
- “Delgocitinib”, 6 entries
- “LEO 124249”, 2 entries
- “LEO 124249 ointment”, 1 entry
- “Delgocitinib capsule”, 1 entry
Conditions, from the studies’ own filings
- Eczema, 9 studies
- Psoriasis, 2 studies
- Dermatitis, Atopic, 2 studies
- Alopecia Areata, 2 studies
- Lichen Sclerosus et Atrophicus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.